Visibly clearer skin for teens
In a clinical study of teens (ages 12-17) with moderate-to-severe eczema who used topical steroids with either CIBINQO or an inactive pill after 3 MONTHS:
The majority taking CIBINQO saw 75% SKIN IMPROVEMENT
Some taking CIBINQO saw CLEAR OR ALMOST CLEAR SKIN
The recommended starting dose of CIBINQO is 100 mg once daily.
If the 100 mg dose isn't working well after 3 months, your doctor may increase your dose to 200 mg once daily. If the 200 mg dose isn't working well, your doctor may advise you to stop CIBINQO.
Some taking CIBINQO felt FAST ITCH RELIEF IN JUST 2 WEEKS
CIBINQO delivered effective itch relief in 2 weeks (13% taking 100 mg, 25% taking 200 mg) vs an inactive pill (8%).
Studies of the safety and effectiveness of CIBINQO showed results in teens (ages 12-17) were consistent with results in adults (18+)
The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count. These are not all of the possible side effects of CIBINQO. For more information, talk to your doctor or learn more about the Most Important Information about CIBINQO.
One of the clinical trials for CIBINQO focused on teens (ages 12-17) with moderate-to-severe eczema. Participants received either CIBINQO or an inactive pill (also known as a placebo). Neither they nor their doctors were told which one they received. All of those studied used topical steroids and had the option to also use a moisturizer.
This trial lasted 3 months and focused on understanding the effectiveness and safety of CIBINQO. Improvement in area and severity of eczema-affected skin, skin clearance, and itch reduction were monitored.
Some of the participants were able to enter another longer-term study that focused on safety.
Skin improvement, skin clearance, and itch reduction were monitored before, during, and at the end of the trials. The goal was to help answer the following question: Are teens who take CIBINQO more likely to have their eczema improve compared to teens who do not take CIBINQO?
Who participated in the teen study?
Pfizer would like to thank everyone who participated in the CIBINQO clinical trials.
Seeing is believing
Take a look at before-and-after photos of adults from our clinical trials to see results some people with moderate-to-severe eczema experienced.